Introduction
============

Type 1 diabetes is the predominant form of diabetes diagnosed in childhood and is characterised by increased blood glucose levels resulting from insulin deficiency. Treatment in developed countries generally comprises exogenous insulin by injections or insulin pump as guided by capillary testing or use of continuous glucose monitoring to estimate blood glucose levels. Intensive treatment with better glycaemic control has been shown to reduce the risk of retinopathy and nephropathy, with a strong association between glycated haemoglobin (HbA~1c)~ level and diabetes complications.[@ref1] [@ref2] [@ref3] [@ref4]

Multiple studies in several countries have confirmed that a higher HbA~1c~ level is an independent risk factor for diabetes complications.[@ref1] [@ref2] [@ref3] [@ref4] [@ref5] [@ref6] [@ref7] [@ref8] [@ref9] [@ref10] Few studies have followed patients from diagnosis, therefore large contemporary population based studies evaluating the relation between HbA~1c~ levels and diabetes complications would complement earlier studies to help understand the risks of complications during modern glucose lowering treatments.

The evidence for HbA~1c~ levels and diabetes complications is interpreted differently by organisations such as the American Diabetes Association and International Society for Paediatric and Adolescent Diabetes, resulting in guidelines that differ between organisations and countries---current guidelines range between 6.5% (48 mmol/mol) and 7.5% (58 mmol/mol).[@ref11] [@ref12] [@ref13] [@ref14] HbA~1c~ targets also differ within countries for children and adults. Reaching lower HbA~1c~ levels requires greater effort from people with diabetes and their families and can be associated with more stress and possibly an increased risk of hypoglycaemia, which in itself can be burdensome and lead to unconsciousness.[@ref1] [@ref15] [@ref16] If major risk reductions of long term complications could be obtained with low HbA~1c~ levels this might outweigh a potentially increased risk of hypoglycaemia and the efforts needed to achieve low levels.

To understand better the relation between HbA~1c~ level and microvascular complications in people with type 1 diabetes, we utilised the paediatric and adult diabetes registries in Sweden. Participants were followed-up regarding retinopathy and nephropathy for 8-20 years from diagnosis.

Methods
=======

This is a nationwide population based observational cohort study. Participants provided informed consent.

Data sources
------------

The Swedish Diabetes Registry for adults recently merged with Swediabkids, the paediatric registry for diabetes established in 2000. Since 1996 the Swedish Diabetes Registry has included information on risk factors, drugs, and complications and is described in detail elsewhere.[@ref9] [@ref13] [@ref17] More than 95% of Swedish children and adolescents with type 1 diabetes are registered in the Swediabkids database, which consists of outpatient data from all paediatric diabetes centres in Sweden.[@ref18] Since 2007 the registry has included data on almost all (98%) children and adolescents with diabetes in Sweden. In this study we included information from the Swedish Diabetes Registry for 1998 onwards and from Swediabkids for 2000 onwards.

Study cohort
------------

In the Swedish Diabetes Registry, type 1 diabetes was defined as treatment with insulin and diagnosis at age 30 years or younger, and this definition has been validated in 97% of cases.[@ref17] We also required that a clinician had recorded a diagnosis of type 1 diabetes in the registry. Swediabkids used the recorded diagnosis of type 1 diabetes. HLA and autoantibodies are determined in all children with newly diagnosed diabetes.

We included children and adults with a diagnosis of diabetes for five or less years when first recorded in the registries. Endpoints of retinopathy were classified as any retinopathy, preproliferative diabetic retinopathy or worse, and proliferative diabetic retinopathy. Any retinopathy included any signs of retinopathy (simplex, preproliferative, or proliferative). Proliferative diabetic retinopathy was defined as evidence of current proliferations or earlier laser photocoagulation. Microalbuminuria was defined as two positive test results from three samples taken within one year, with an albumin:creatinine ratio of 3-30 mg/mmol or urinary albumin of 20-200 µg/min (20-300 mg/L), and macroalbuminuria as an albumin:creatinine ratio \>30 mg/mmol or urinary albumin \>200 µg/min (\>300 mg/L).

Procedures
----------

As follow-up periods differed for participants because of being included in the register at different times, we categorised subcohorts by follow-up time from diabetes onset: 8-9, 10-11, 12-13, 14-15, and 16-20 years. We followed participants from the first observation until first retinopathy or nephropathy event, 31 December 2017, or end of each follow-up if censored earlier. Participants were categorised by glycaemic control based on area under the curve, a weighted mean value calculated using the trapezoidal method that takes into consideration the interval between HbA~1c~ measurements.[@ref5] [@ref10] Descriptive data were analysed for each cohort. To increase study power and obtain overall effects of HbA~1c~ categories we pooled estimates for the primary analysis of HbA~1c~ levels and risk of complications.

Analyses of HbA~1c~ are reported according to the International Federation of Clinical Chemistry standard, measured in mmol/mol. Laboratory methods at participating care units for analysing HbA~1c~ level and albuminuria are regularly checked with central reference samples of HbA~1c~ and albuminuria to ensure high accuracy.[@ref19] [@ref20] HbA~1c~ values were converted to levels according to the National Glycohemoglobin Standardization Program for dual reporting.[@ref21] We evaluated HbA~1c~ as a categorical variable (\<6.5% (\<48 mmol/mol), 6.5-6.9 (48-52 mmol/mol), 7.0-7.4 (53-57 mmol/mol), 7.5-8.6 (58-70 mmol/mol), and \>8.6% (\>70 mmol/mol) and estimated risk of complications in relation to HbA~1c~ level as a continuous variable for each 1% (10 mmol/mol). We performed unadjusted analyses and in the main model we adjusted for age, sex, duration of diabetes, blood pressure, blood lipid levels, body mass index, and smoking.

Since 2008 severe hypoglycaemias (defined as unconsciousness or seizures) have been recorded in Swediabkids and were analysed at each visit according to HbA~1c~ categories in three steps. Firstly, participants were followed-up from first available hypoglycaemia data from 2008 and onwards, with HbA~1c~ area under the curve counted from earliest one year before first registration of hypoglycaemic data (main hypoglycaemia analysis). Secondly, participants were included in the main hypoglycaemia analysis, including those with date of diabetes onset on or after first registration of hypoglycaemic data (first sensitivity hypoglycaemia analysis). Finally, only participants who were part of the main retinopathy and albuminuria analyses were included in the second sensitivity hypoglycaemia analysis.

Statistical analysis
--------------------

We present numbers and percentages (with 95% confidence intervals) of complications for each category of HbA~1c~. Logistic regression was used to estimate the relation between HbA~1c~ level and diabetes complications using odds ratios (95% confidence intervals) as risk estimates for different follow-up cohorts, and c statistics for goodness of fit. Analyses were performed by categories of HbA~1c~ level, with 6.5-6.9% (48-52 mmol/mol) as the reference category and as a continuous variable for each 1% (10 mmol/mol) HbA~1c~, with splines also used to examine non-linear effects. We applied Firth's penalised maximum likelihood estimation to reduce bias in the parameter estimates in the analyses with low number of events, leading to non-estimable coefficients or 95% confidence intervals. Generalised estimating equations modelling was used to estimate an overall effect of HbA~1c~ categories on studied endpoints and to adjust for within patient correlation for repeated data over the follow-up cohorts.[@ref22] [@ref23] This model therefore allows a participant to be included in more than one cohort. We used unstructured covariance matrix and binomial distribution with logit link function, resulting in odds ratios (95% confidence intervals) as risk estimates.

Hypoglycaemic events were analysed using Poisson regression with log-link function and time from onset to event or last follow-up as an offset timing variable, to have event rates as the basis of the calculations instead of experience of an event only. Relative risks (95% confidence intervals) are provided as effect size.

No data were imputed. Tests were two tailed and conducted at 0.05 significance level. All statistical programming was performed using SAS Software version 9.4 (SAS Institute, Cary, NC).

Patient and public involvement
------------------------------

This research was done without patient involvement. Patients were not invited to comment on the study design and were not consulted to develop patient relevant outcomes or interpret the results. Patients were not invited to contribute to the writing or editing of this document for readability or accuracy.

Results
=======

Participant characteristics
---------------------------

In total 10 398/11 009 (94.4%) children and adults with type 1 diabetes for more than eight years and early onset diabetes had information on HbA~1c~ level and complications and were included in the analyses (see supplementary figure 1). The mean duration of diabetes at registration was 1.3 years (median 0.4 years) and at last follow-up was 11.9 years (median 10.4 years). Mean age at first visit was 14.7 years, 43.4% (4515/10 398) were female, and mean HbA~1c~ area under the curve during follow-up was 8.0% (63.4 mmol/mol), with a mean number of HbA~1c~ values per year of 2.7 (median 2.7). [Table 1](#tbl1){ref-type="table"} presents the characteristic of participants by cohort (see supplementary table 1 for data used as covariates in analyses).

###### 

Patient characteristics for population with recorded retinopathy and albuminuria data at a clinical visit during selected years follow-up from diabetes onset. Values are numbers (percentages) unless stated otherwise

  Variables                     Duration of follow-up (years)                                                                                                                                                                               
  ----------------------------- ------------------------------- ------------------- -- ------------------- ------------------- -- ------------------- ------------------- -- ------------------- ------------------- -- ------------------- -------------------
  Age at first visit (years):                                                                                                                                                                                                               
   Mean (SD)                    14.7 (7.9)                      18.1 (7.3)             12.6 (7.1)          15.1 (7.1)             9.19 (3.67)         10.1 (3.4)             8.88 (3.40)         9.34 (3.29)            8.65 (3.12)         8.84 (3.20)
   Median (min-max)             13.0 (0.0-34.0)                 18.0 (0.6-34.0)        11.1 (0.0-34.0)     13.2 (0.0-34.0)        9.24 (0.00-19.71)   10.1 (0.4-19.9)        8.91 (0.00-19.71)   9.43 (0.66-19.89)      8.65 (0.79-19.70)   8.84 (0.79-19.71)
  Female                        3481 (43.2)                     2748 (42.4)            2412 (45.3)         2036 (45.3)            1447 (47.5)         1301 (49.2)            941 (48.8)          977 (49.9)             566 (48.3)          608 (48.2)
  Year of onset:                n=8046                          n=6476                 n=5319              n=4490                 n=3042              n=2642                 n=1925              n=1959                 n=1166              n=1262
   Mean (SD)                    2003 (4)                        2004 (4)               2003 (3)            2003 (3)               2002 (2)            2002 (2)               2000 (2)            2000 (2)               1999 (2)            1999 (2)
   Median (min-max)             2004 (1993-2009)                2004 (1993-2009)       2003 (1993-2007)    2004 (1993-2007)       2002 (1995-2005)    2002 (1995-2005)       2001 (1995-2003)    2001 (1995-2003)       1999 (1995-2001)    1999 (1995-2001)
  HbA~1c~ (mmol/mol):                                                                                                                                                                                                                       
   Mean (SD)                    62.4 (11.2)                     62.2 (12.2)            63.7 (10.7)         63.9 (11.7)            65.6 (10.0)         66.3 (10.5)            66.3 (9.9)          67.0 (10.3)            66.7 (10.3)         67.0 (10.3)
   Median (min-max)             61.5 (29.0-124.3)               61.0 (29.0-124.3)      62.9 (29.1-129.7)   62.8 (29.1-129.7)      64.5 (33.9-124.7)   65.0 (33.9-124.7)      65.0 (41.2-116.0)   65.5 (41.2-120.9)      65.4 (44.0-108.6)   65.6 (44.0-109.9)
  HbA~1c~ (%):                                                                                                                                                                                                                              
   Mean (SD)                    7.86 (1.02)                     7.84 (1.11)            7.98 (0.98)         8.00 (1.07)            8.16 (0.91)         8.22 (0.96)            8.22 (0.91)         8.28 (0.94)            8.26 (0.94)         8.28 (0.94)
   Median (min-max)             7.78 (4.81-13.53)               7.73 (4.81-13.53)      7.90 (4.81-14.02)   7.90 (4.81-14.02)      8.06 (5.25-13.57)   8.10 (5.25-13.57)      8.10 (5.92-12.77)   8.15 (5.92-13.21)      8.14 (6.18-12.09)   8.15 (6.18-12.21)
  HbA~1c~ AUC category\*:                                                                                                                                                                                                                   
   \<6.5%                       625 (7.8)                       661 (10.2)             271 (5.1)           277 (6.2)              49 (1.6)            45 (1.7)               20 (1.0)            21 (1.1)               10 (0.9)            8 (0.6)
   6.5-6.9%                     871 (10.8)                      789 (12.2)             489 (9.2)           452 (10.1)             186 (6.1)           157 (5.9)              101 (5.2)           89 (4.5)               61 (5.2)            62 (4.9)
   7.0-7.4%                     1415 (17.6)                     1106 (17.1)            858 (16.1)          702 (15.6)             434 (14.3)          364 (13.8)             244 (12.7)          238 (12.1)             152 (13.0)          163 (12.9)
   7.5-8.6%                     3420 (42.5)                     2429 (37.5)            2408 (45.2)         1862 (41.5)            1534 (50.4)         1268 (48.0)            983 (51.0)          974 (49.7)             587 (50.1)          623 (49.4)
   \>8.6%                       1718 (21.3)                     1491 (23.0)            1298 (24.4)         1197 (26.7)            841 (27.6)          808 (30.6)             579 (30.0)          637 (32.5)             362 (30.9)          406 (32.2)

AUC=area under the curve.

\<6.5% (\<48 mmol/mol); 6.5-6.9% (48-52 mmol/mol); 7.0-7.4% (53-57 mmol/mol); 7.5-8.6% (58-70 mmol/mol); \>8.6% (\>70 mmol/mol).

HbA~1c~ level and microvascular complications
---------------------------------------------

[Table 2](#tbl2){ref-type="table"} shows the unadjusted and adjusted risk of retinopathy (simplex, preproliferative, and proliferative) in relation to HbA~1c~ level of 6.5-6.9% (48-52 mmol/mol) for all follow-up cohorts using generalised estimating equation models and number of events. Overall, 9358 children and adults were included in analyses of retinopathy of whom 3115 (33.3%) had any retinopathy event. The number of participants with preproliferative diabetic retinopathy was 284 (3.0%) and with proliferative diabetic retinopathy was 106 (1.1%). The risk of any retinopathy (simplex or worse) for participants with an HbA~1c~ level \<6.5% (\<48 mmol/mol) compared with 6.5-6.9% (48-52 mmol/mol) did not differ: unadjusted odds ratio 0.85 (95% confidence interval 0.63 to 1.13, P=0.25) and adjusted odds ratio 0.77 (0.56 to 1.05, P=0.10). The risk of retinopathy was increased in participants with HbA~1c~ levels of 7.0-7.4% (53-57 mmol/mol), with an adjusted odds ratio of 1.31 (1.05 to 1.64, P=0.02), and the risk was higher in those with HbA~1c~ levels of 7.5-8.6% (58-70 mmol/mol) and \>8.6% (\>70 mmol/mol) ([table 2](#tbl2){ref-type="table"}).

###### 

Generalised estimating equation models for association between glycated haemoglobin (HbA~1c~) categories on diabetic retinopathy and albuminuria endpoints pooled over all studied periods

  Endpoint by HbA~1c~ category\*                      No of events   \% (95% CI)           No of participants with events   \% (95% CI)              Unadjusted              Adjusted†                           
  --------------------------------------------------- -------------- --------------------- -------------------------------- --------------------- -- ----------------------- ----------- ----------------------- ---------
  Any retinopathy *v* none:                                                                                                                                                                                      
   \<6.5%                                             85             8.7 (7.0 to 10.7)     75                               11.0 (8.9 to 13.7)       0.85 (0.63 to 1.13)     0.25        0.77 (0.56 to 1.05)     0.10
   6.5-6.9%                                           214            12.5 (11.0 to 14.2)   159                              14.7 (12.7 to 17.0)      1.00 (Ref)                          1.00 (Ref)              
   7.0-7.4%                                           480            15.5 (14.2 to 16.8)   364                              20.0 (18.2 to 21.9)      1.25 (1.03 to 1.52)     0.02        1.31 (1.05 to 1.64)     0.02
   7.5-8.6%                                           2199           24.6 (23.7 to 25.5)   1445                             33.1 (31.7 to 34.5)      2.01 (1.68 to 2.40)     \<0.001     2.05 (1.68 to 2.51)     \<0.001
   \>8.6%                                             2006           41.8 (40.4 to 43.2)   1211                             51.0 (49.0 to 53.0)      4.11 (3.43 to 4.93)     \<0.001     3.72 (3.02 to 4.58)     \<0.001
  PPDR/PDR/laser photocoagulation *v* none/simplex:                                                                                                                                                              
   \<6.5%                                             8              0.8 (0.4 to 1.6)      7                                1.0 (0.5 to 2.3)         3.74 (1.19 to 11.76)    0.02        3.29 (0.99 to 10.96)    0.05
   6.5-6.9%                                           5              0.3 (0.1 to 0.7)      5                                0.5 (0.2 to 1.2)         1.00 (Ref)                          1.00 (Ref)              
   7.0-7.4%                                           12             0.4 (0.2 to 0.7)      9                                0.5 (0.3 to 1.0)         1.12 (0.36 to 3.50)     0.85        1.57 (0.49 to 5.03)     0.45
   7.5-8.6%                                           92             1.0 (0.8 to 1.3)      78                               1.8 (1.4 to 2.2)         2.77 (1.08 to 7.08)     0.03        3.98 (1.44 to 10.98)    0.008
   \>8.6%                                             250            5.2 (4.6 to 5.9)      186                              7.8 (6.8 to 9.0)         13.44 (5.34 to 33.85)   \<0.001     13.77 (5.08 to 37.35)   \<0.001
  PDR/laser photocoagulation *v* none/simplex/PPDR:                                                                                                                                                              
   \<6.5%                                             6              0.6 (0.2 to 1.3)      6                                0.9 (0.4 to 2.1)         4.18 (1.17 to 14.90)    0.03        2.48 (0.71 to 8.62)     0.15
   6.5-6.9%                                           4              0.2 (0.1 to 0.6)      4                                0.4 (0.2 to 1.1)         1.00 (Ref)                          1.00 (Ref)              
   7.0-7.4%                                           7              0.2 (0.1 to 0.5)      5                                0.3 (0.1 to 0.7)         0.85 (0.22 to 3.26)     0.82        0.80 (0.20 to 3.22)     0.75
   7.5-8.6%                                           24             0.3 (0.2 to 0.4)      20                               0.5 (0.3 to 0.7)         0.97 (0.32 to 2.96)     0.96        1.14 (0.37 to 3.50)     0.82
   \>8.6%                                             93             1.9 (1.6 to 2.4)      71                               3.0 (2.4 to 3.8)         6.32 (2.21 to 18.11)    \<0.001     5.98 (2.10 to 17.06)    \<0.001
  Microalbuminuria/macroalbuminuria *v* none:                                                                                                                                                                    
   \<6.5%                                             35             3.5 (2.4 to 4.8)      28                               3.9 (2.7 to 5.7)         1.04 (0.66 to 1.66)     0.86        0.98 (0.60 to 1.61)     0.95
   6.5-6.9%                                           53             3.4 (2.6 to 4.5)      40                               3.8 (2.8 to 5.3)         1.00 (Ref)                          1.00 (Ref)              
   7.0-7.4%                                           130            5.1 (4.2 to 6.0)      99                               5.9 (4.9 to 7.2)         1.41 (0.98 to 2.03)     0.06        1.55 (1.03 to 2.32)     0.03
   7.5-8.6%                                           328            4.6 (4.1 to 5.1)      256                              6.2 (5.5 to 7.0)         1.41 (1.01 to 1.98)     0.04        1.33 (0.91 to 1.94)     0.14
   \>8.6%                                             481            10.6 (9.7 to 11.5)    329                              13.4 (12.1 to 14.9)      3.16 (2.27 to 4.41)     \<0.001     2.64 (1.81 to 3.86)     \<0.001
  Macroalbuminuria *v* none/microalbuminuria:                                                                                                                                                                    
   \<6.5%                                             9              0.9 (0.4 to 1.7)      7                                1.0 (0.5 to 2.2)         1.95 (0.67 to 5.74)     0.22        2.47 (0.69 to 8.87)     0.17
   6.5-6.9%                                           6              0.4 (0.1 to 0.8)      6                                0.6 (0.3 to 1.4)         1.00 (Ref)                          1.00 (Ref)              
   7.0-7.4%                                           18             0.7 (0.4 to 1.1)      15                               0.9 (0.5 to 1.5)         1.70 (0.70 to 4.12)     0.24        2.47 (0.83 to 7.35)     0.10
   7.5-8.6%                                           56             0.8 (0.6 to 1.0)      49                               1.2 (0.9 to 1.6)         1.88 (0.82 to 4.31)     0.14        2.11 (0.73 to 6.14)     0.17
   \>8.6%                                             74             1.6 (1.3 to 2.0)      55                               2.2 (1.7 to 3.0)         3.67 (1.62 to 8.30)     0.002       3.43 (1.14 to 10.26)    0.03

PPDR=preproliferative diabetic retinopathy; PDR=proliferative diabetic retinopathy.

\<6.5% (\<48 mmol/mol); 6.5-6.9% (48-52 mmol/mol); 7.0-7.4% (53-57 mmol/mol); 7.5-8.6% (58-70 mmol/mol); \>8.6% (\>70 mmol/mol).

Adjusted for age; sex; mean systolic and diastolic blood pressure, body mass index, high and low density lipoprotein cholesterol, cholesterol, and triglycerides; and smoking.

A different pattern was observed for preproliferative diabetic retinopathy or worse, with risk increases in participants with low HbA~1c~ levels (\<6.5%, \<48 mmol/mol) in unadjusted analysis (odds ratio 3.74, 1.19 to 11.76, P=0.02) and in adjusted analysis (3.29, 0.99 to 10.96, P=0.05), with a risk increase observed for higher HbA~1c~ levels starting at 7.5-8.6% (58-70 mmol/mol): 3.98 (1.44 to 10.98, P=0.008). For the most advanced stage (proliferative diabetic retinopathy or earlier laser photocoagulation), risk increases were observed for participants with low HbA~1c~ levels (\<6.5%, \<48 mmol/mol): odds ratio 4.18 (1.17 to 14.90, P=0.03) in unadjusted analysis and 2.48 (0.71 to 8.62, P=0.15) in adjusted analysis. This pattern became apparent at high HbA~1c~ levels and was significant at \>8.6% (\>70 mmol/mol): 5.98 (2.10 to 17.06, P\<0.001).

Overall, 9347 children and adults were included in analyses of microalbuminuria (n=737, 7.9%) and macroalbuminuria (n=132, 1.4%). The risk for microalbuminuria and macroalbuminuria did not differ between the two lowest (\<6.5% (\<48 mmol/mol) and 6.5-6.9% (48-52 mmol/mol)) HbA~1c~ categories ([table 2](#tbl2){ref-type="table"}). The risk of microalbuminuria increased at HbA~1c~ levels 7.0-7.4% (53-57 mmol/mol) and \>8.6% (\>70 mmol/mol), with adjusted odds ratios of 1.55 (95% confidence interval 1.03 to 2.32, P=0.03) and 2.64 (1.81 to 3.86, P\<0.001), respectively. The risk of macroalbuminuria increased at HbA~1c~ levels \>8.6% (\>70 mmol/mol) compared with HbA~1c~ levels 6.5-6.9% (48-52 mmol/mol), with an adjusted odds ratio of 3.43 (1.14 to 10.26, P=0.03).

Supplementary tables 2.1 and 2.2 present descriptive data for each cohort in the pooled estimations of retinopathy and nephropathy.

Risk of complications over time
-------------------------------

The risk of any retinopathy, preproliferative diabetic retinopathy, and proliferative diabetic retinopathy by 1% (10 mmol/mol) higher HbA~1c~ level increased with longer follow-up ([fig 1](#f1){ref-type="fig"}). The odds ratios for any retinopathy increased from 1.51 (1.42 to 1.62, P\<0.001) for 8-10 years to 1.78 (1.51 to 2.09, P\<0.001) for 16-20 years of follow-up and for proliferative diabetic retinopathy from 1.31 (0.97 to 1.77, P=0.07) to 2.87 (2.18 to 3.79, P\<0.001), respectively. Supplementary table 2.1 shows the crude figures for unadjusted and adjusted odds ratios and corresponding 95% confidence intervals for the values reported in [figure 1](#f1){ref-type="fig"}. Moreover, spline functions (ie, allowing non-linear effects of HbA~1c~ as a continuous variable in relation to complications) indicated that the HbA~1c~ level associated with severe retinopathy decreased over time ([fig 2](#f2){ref-type="fig"}). This trend was most pronounced for the longest follow-up period, of 16-20 years.

![Adjusted odds ratios (95% confidence intervals) for retinopathy and nephropathy for 10 mmol/mol increase in glycated haemoglobin (HbA~1c~) area under curve. y axis is on logarithmic scale. Proliferative diabetic retinopathy/laser photocoagulation and macroalbuminuria adjusted only for age and sex owing to small number of events; other outcomes adjusted for age, sex, mean systolic and mean diastolic blood pressure, mean body mass index, mean high and mean low density lipoprotein cholesterol, mean cholesterol, mean triglycerides, and smoking. PPDR=preproliferative diabetic retinopathy; PDR=proliferative diabetic retinopathy. Whiskers represent 95% confidence intervals](linm050180.f1){#f1}

![Estimated cumulative probability for preproliferative diabetic retinopathy or worse (PPDR), proliferative diabetic retinopathy (PDR), and laser photocoagulation for different area under the curve (AUC) glycated haemoglobin (HbA~1c)~ values allowing for non-linear relation using spline functions for follow-up cohorts. Shaded areas represent 95% confidence intervals](linm050180.f2){#f2}

The odds ratios for microalbuminuria and macroalbuminuria increased for each 1% (10 mmol/mol) higher HbA~1c~ value during follow-up ([fig 1](#f1){ref-type="fig"}, supplementary table 2.2), ranging from 1.31 (1.20 to 1.43, P\<0.001) and 1.23 (1.04 to 1.46, P=0.02) for 8-10 years to 2.14 (1.71 to 2.68, P\<0.001) and 3.83 (2.58 to 5.70, P\<0.001) for 16-20 years, respectively.

Microvascular complications in relation to age and sex
------------------------------------------------------

After adjustment for HbA~1c~ categories and sex, older age at first visit was associated with increased risk for retinopathy and nephropathy; odds ratio for each five years increase was 1.18 for any retinopathy; 1.72 for preproliferative diabetic retinopathy or worse, proliferative diabetic retinopathy, or laser photocoagulation; 1.95 for proliferative diabetic retinopathy or laser photocoagulation; 1.20 for microalbuminuria or macroalbuminuria; and 1.36 for macroalbuminuria; all P values \<0.001.

Risk for retinopathy was not related to sex, but in females the risk was increased for microalbuminuria or macroalbuminuria (1.30, 1.11 to 1.53, P=0.001) and macroalbuminuria (1.51, 1.06 to 2.16, P=0.02).

Proliferative diabetic retinopathy and nephropathy at low HbA~1c~ levels
------------------------------------------------------------------------

Post hoc descriptive analyses were carried out on seven participants with macroalbuminuria and six with proliferative diabetic retinopathy (12 participants in total), within the HbA~1c~ category \<6.5% (\<48 mmol/mol) (see supplementary table 1). Mean time from diabetes onset to first HbA~1c~ measurement was 1.6 years (median 0.8 years) for those with HbA~1c~ levels \<6.5% (\<48 mmol/mol) and no specified endpoints and 2.2 years (median 2.3 years) for those with any of the specified endpoints. Mean number of HbA~1c~ measurements annually ranged between 1.7 and 2.7 among the cohorts, mean age at first visit 20.2 versus 22.7 years, smoking 80/769 (11.3%) versus 0/12 (0%), systolic blood pressure 117.9 versus 119.6 mm Hg, diastolic blood pressure 70.5 versus 72.0 mm Hg, body mass index 23.1 versus 21.9, high density lipoprotein cholesterol 1.6 versus 1.6 mmol/L, and low density lipoprotein cholesterol 2.4 versus 2.1 mmol/L, respectively.

Severe hypoglycaemias
---------------------

The risk of severe hypoglycaemia was observed to be increased at mean HbA~1c~ \<6.5% (\<48 mmol/mol) compared with 6.5-6.9% (48-52 mmol/mol, relative risk 1.34, 95% confidence interval 1.09 to 1.64, P=0.005). An association was also found between lower risk of severe hypoglycaemia with higher HbA~1c~ level (0.79 (0.75 to 0.83) for each 1% (10 mmol/mol) higher mean HbA~1c~, P\<0.001). Compared with the reference category 6.5-6.9% (48-52 mmol/mol), the relative risk for the highest category of HbA~1c~ \>8.6% (\>70 mmol/mol) was 0.53 (95% confidence interval 0.43 to 0.64, P\<0.001). The two sensitivity analyses led to similar conclusions to the main hypoglycaemia analysis ([table 3](#tbl3){ref-type="table"}).

###### 

Poisson regression for impact of continuous glycated haemoglobin (HbA~1c~) and categories on severe hypoglycaemic events

  Population/analysis and comparison                                                                                                                                                                      Relative risk (95% CI)   P value
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ ---------
  **Swediabkids main: from first available hypoglycaemia data 2008 onwards with HbA~1c~ counted from earliest 1 year before first registration of hypoglycaemic data n/N (%) events 1398/13413 (10.4)**                            
  HbA~1c~ AUC category\*:                                                                                                                                                                                                          
   By 1% increase                                                                                                                                                                                         0.79 (0.75 to 0.83)      \<0.001
   6.5-6.9% *v* 6.5-6.9%                                                                                                                                                                                  1.00 (Ref)               
   \<6.5% *v* 6.5-6.9%                                                                                                                                                                                    1.34 (1.09 to 1.64)      0.005
   7.0-7.4% *v* 6.5-6.9%                                                                                                                                                                                  0.88 (0.74 to 1.06)      0.19
   7.5-8.6% *v* 6.5-6.9%                                                                                                                                                                                  0.83 (0.71 to 0.98)      0.03
   \>8.6% *v* 6.5-6.9%                                                                                                                                                                                    0.53 (0.43 to 0.64)      \<0.001
  **Swediabkids first sensitivity analysis, main including those participants with onset date on or after first registration of hypoglycaemic data n/N (%) events725/8271 (8.8%)**                                                 
   By 1% increase                                                                                                                                                                                         0.88 (0.81 to 0.96)      0.003
   6.5-6.9% *v* 6.5-6.9%                                                                                                                                                                                  1.00 (Ref)               
   \<6.5% *v* 6.5-6.9%                                                                                                                                                                                    1.30 (1.04 to 1.63)      0.02
   7.0-7.4% *v* 6.5-6.9%                                                                                                                                                                                  0.91 (0.73 to 1.14)      0.40
   7.5-8.6% *v* 6.5-6.9%                                                                                                                                                                                  0.96 (0.78 to 1.18)      0.68
   \>8.6% *v* 6.5-6.9%                                                                                                                                                                                    0.79 (0.56 to 1.12)      0.18
  **Swediabkids second sensitivity analysis−first sensitivity+including only those participants from the main retinopathy/albuminuria analyses n/N (%) events: 217/1359 (16.0%)**                                                  
   By 1% increase                                                                                                                                                                                         0.75 (0.64 to 0.88)      \<0.001
   6.5-6.9% *v* 6.5-6.9%                                                                                                                                                                                  1.00 (Ref)               
   \<6.5% *v* 6.5-6.9%                                                                                                                                                                                    2.10 (1.32 to 3.34)      0.002
   7.0-7.4% *v* 6.5-6.9%                                                                                                                                                                                  0.86 (0.55 to 1.34)      0.51
   7.5-8.6% *v* 6.5-6.9%                                                                                                                                                                                  0.91 (0.62 to 1.36)      0.66
   \>8.6% *v* 6.5-6.9%                                                                                                                                                                                    0.58 (0.31 to 1.10)      0.10

AUC=area under the curve.

\<6.5% (\<48 mmol/mol); 6.5-6.9% (48-52 mmol/mol); 7.0-7.4% (53-57 mmol/mol); 7.5-8.6% (58-70 mmol/mol); \>8.6% (\>70 mmol/mol).

Discussion
==========

This study of 10 398 children and adults followed for 8-20 years from diagnosis of type 1 diabetes or shortly thereafter did not find any statistically significant differences in risk for retinopathy or nephropathy for a mean glycated haemoglobin (HbA~1c~) level of \<6.5% (\<48 mmol/mol) compared with 6.5-6.9% (48-52 mmol/mol). Any retinopathy (defined as simplex or worse) and microalbuminuria became slightly more common at mean HbA~1c~ levels greater than 7.0% (53 mmol/mol), whereas increasing risk of preproliferative diabetic retinopathy (moderately severe) started at HbA~1c~ levels around 7.5% (58 mmol/mol). Severe complications in the form of proliferative diabetic retinopathy and macroalbuminuria first became apparent at mean HbA~1c~ levels \>8.6% (\>70 mmol/mol). Severe hypoglycaemia increased with lower HbA~1c~ levels and was greater at levels \<6.5% (\<48 mmol/mol) compared with 6.5-6.9% (48-52 mmol/mol).

Comparison with other studies
-----------------------------

Multiple studies of HbA~1c~ related to diabetes complications, both microvascular and macrovascular, have been performed.[@ref1] [@ref2] [@ref3] [@ref4] [@ref5] [@ref6] [@ref7] [@ref8] [@ref9] [@ref10] To fully understand the impact of HbA~1c~ levels, studies should preferentially be performed in larger populations and follow participants from childhood, when onset of type 1 diabetes generally occurs, to adulthood, when complications most often exist.[@ref3] [@ref4] [@ref10] The Diabetes Control and Complications Trial is evaluating participants in the primary prevention cohort (n=726) from diagnosis or closely thereafter and showed the strongest relations between HbA~1c~ and complications in this cohort compared with the secondary intervention cohort including people with longer duration of diabetes and existing complications.[@ref1] [@ref2] [@ref24] About half of the participants in the Diabetes Control and Complications Trial were treated with multiple dose insulin injections or insulin pumps, whereas the rest had only basal insulin. Because relatively few complications occurred at lower HbA~1c~ levels, however, it is difficult to distinguish between differences in risk at low HbA~1c~ levels, such as \<6.5% (\<48 mmol/mol) compared with \<7.0% (\<53 mmol/mol). A study that followed 451 participants from diagnosis to 20-24 years onwards found no cases of proliferative diabetic retinopathy at a mean HbA~1c~ level of \<7.6% (\<60 mmol/mol), and no participant developed macroproteinuria at HbA~1c~ \<8.4% (\<68 mmol/mol).[@ref4] The current study complements earlier studies as it is larger, population based, and includes participants who used modern glucose lowering treatments.

HbA~1c~ targets
---------------

Currently, HbA~1c~ targets vary in diabetes guidelines worldwide.[@ref11] [@ref12] [@ref13] [@ref14] In the US, the American Diabetes Association guidelines recommend an HbA~1c~ of \<7.5% (\<58 mmol/mol) for children and \<7.0% (\<53 mmol/mol) for adults.[@ref11] In the UK, the National Institute for Health and Care Excellence recommends \<6.5% (\<48 mmol/mol) for both children and adults, whereas Swedish guidelines recommend \<6.5% (\<48 mmol/mol) for children and \<7.0% (\<53 mmol/mol) for adults.[@ref12] [@ref13] The International Society for Pediatric and Adolescent Diabetes has recently lowered the HbA~1c~ target from \<7.5% (\<58 mmol/mol) to \<7.0% (\<53 mmol/mol).[@ref14]

Clinical implications
---------------------

Reaching lower HbA~1c~ targets is associated with increased effort by people with type 1 diabetes[@ref15] and not least for carers of children with diabetes.[@ref16] Glucose levels must be checked often, insulin administered frequently, and certain things undertaken, such as following a suitable diet or ensuring physical activity. Both children and their parents often need to make substantial efforts in their daily lives, which can include overnight glucose monitoring and extra insulin doses to reach HbA~1c~ targets. People with type 1 diabetes can be frustrated from having to monitor the disease, and diabetes can be associated with increased stress.[@ref15] [@ref16] It is therefore clinically important to know if a low HbA~1c~ target of \<6.5% (\<48 mmol/mol) can prevent microvascular complications more than a HbA~1c~ target of \<7.0% (\<53 mmol/mol).

In this study, preproliferative diabetic retinopathy or worse occurred in seven participants with a mean HbA~1c~ level of \<6.5% (\<48 mmol/mol), which was associated with an increased risk of borderline significance (P=0.05) versus an HbA~1c~ level of 6.5-6.9% (48-52 mmol/mol), and seven participants developed macroalbuminuria. It seems unlikely that low HbA~1c~ levels indicating glucose levels close to normal should be harmful in themselves; however, preclinical studies have indicated that microvascular complications might be promoted by frequent hypoglycaemia, as is possibly the case with rapid glucose fluctuations that can be related to hypoglycaemia.[@ref25] [@ref26] Moreover, we observed an increased risk of severe hypoglycaemia with HbA~1c~ levels \<6.5% (\<48 mmol/mol) compared with 6.5-6.9% (48-52 mmol/mol).

Hence the current findings suggest that clinicians should be extra vigilant about ensuring people with diabetes do not spend considerable time in hypoglycaemia and that treatment is related to good quality of life at HbA~1c~ levels \<6.5% (\<48 mmol/mol) or else aim at higher levels of 6.5-6.9% (48-52 mmol/mol). The rationale being that we do not find any further reduction of risk for microvascular complications at HbA~1c~ levels \<6.5% (\<48 mmol/mol) in this large cohort compared with levels of 6.5-6.9% (48-52 mmol/mol).

Future studies
--------------

In future studies it will be important to include data based on continuous and flash glucose monitors over a long period.[@ref27] In such studies it will also be important to evaluate complementary glycaemic metrics to HbA~1c~, including measures for euglycaemia, time in hypoglycaemia, and glycaemic variability.

HbA~1c~ levels and cardiovascular disease
-----------------------------------------

When discussing at what HbA~1c~ levels clinicians should be aware that risk reductions exist and evidence from guidelines it is essential to also discuss relations between HbA~1c~ level and cardiovascular disease. In a recent study of more than 30 000 people with type 1 diabetes, risk estimates for myocardial infarction were in principle identical for those with mean HbA~1c~ levels \<6.5% (\<48 mmol/mol) compared with 6.5-7.0% (48-53 mmol/mol).[@ref9] Although information on mean level of HbA~1c~ was available over about nine years, a limitation was that glycaemic control further back in the patient´s history was not known in many patients, known to be crucial for future complications termed metabolic memory or legacy effects.[@ref28]

HbA~1c~ levels and advanced microvascular complications
-------------------------------------------------------

In the current study, complications were statistically significantly more advanced in participants with HbA~1c~ levels \>8.6% (\>70 mmol/mol)---that is, proliferative diabetic retinopathy and macroalbuminuria at 10-20 years after diagnosis. Also, the tendency was for more advanced complications to appear after 16-20 years at lower HbA~1c~ levels. Hence clinicians need to focus on lowering high HbA~1c~ levels at least to moderately increased levels in addition to targeting HbA~1c~.

Exposure time and risk
----------------------

The risk association between HbA~1c~ level and complications increased with longer follow-up, and relative risks were generally higher than earlier described.[@ref1] [@ref2] [@ref3] [@ref4] [@ref5] [@ref6] [@ref7] [@ref8] During follow-up of 16-20 years, a 1% (10 mmol/mol) increase in HbA~1c~ level resulted in an odds ratio of 2.87 for proliferative diabetic retinopathy and of 3.83 for macroalbuminuria. This is important for economic analyses and decision making about diabetes treatments as an essential part of health economic analyses within the specialty of diabetes is the association between HbA~1c~ level and risk of complications.

Future treatments
-----------------

Treatments for type 1 diabetes are emerging that could influence the possibilities of reaching low HbA~1c~ levels with a low risk of hypoglycaemia in the future. Continuous glucose monitoring, in conjunction both with and without an insulin pump, have shown beneficial effects in reducing both HbA~1c~ levels and time in hypoglycaemia and is becoming more commonly used among people with type 1 diabetes.[@ref29] [@ref30] [@ref31] [@ref32] Moreover, oral treatment with sodium-glucose cotransporter 2 inhibitors has shown beneficial effects in reducing HbA~1c~ levels without increasing the risk of hypoglycaemia when added to insulin treatment in adults with type 1 diabetes.[@ref33] [@ref34] This treatment will likely soon be introduced in clinical practice. However, broad use might initially be limited owing to increased risk of diabetes ketoacidosis before it can be better understood who is at risk and how ketoacidosis can best be prevented.

Strengths and limitations of this study
---------------------------------------

The main strength of this study is follow-up of a large nationwide population from diagnosis of type 1 diabetes, with data collection up to 31 December 2017. Treatments have shifted over time and risk patterns might differ during recent decades, with more people receiving modern insulin analogues and continuous glucose monitoring known to reduce the risk of hypoglycaemia while lowering HbA~1c~ levels.[@ref35] [@ref36] Although relatively few advanced complications occurred, the study was relatively highly powered to detect these, as shown by the narrow confidence intervals. Limitations include the decreasing number of people with longer follow-up and retrospective study design; the lack of more detailed information on hypoglycaemia, including continuous glucose monitoring results for time in hypoglycaemia; and information on insulin doses, pregnancy, and concurrent illnesses. Moreover, information on quality of life was not available. The current study did not include macrovascular endpoints since these events generally occur later in life and would require long follow-up. Microalbuminuria and macroalbuminuria evaluated here are some of the strongest risk factors for future cardiovascular risk and mortality.[@ref9] [@ref37] A further limitation is that we cannot exclude the influence of other renal diseases on albuminuria levels in certain cases. However, the strong risk gradients found between HbA~1c~ level and nephropathy indicate a high overall quality of data, and the variables have been used in multiple earlier studies based on Swedish registry data.[@ref9] [@ref13] [@ref37]

Conclusions
-----------

We found no difference in risk of retinopathy and nephropathy at HbA~1c~ levels \<6.5% (\<48 mmol/mol) but an increased risk of severe hypoglycaemia compared with levels of 6.5-6.9% (48-52 mmol/mol). Severe complications mainly occurred at HbA~1c~ levels \>8.6% (\>70 mmol/mol), whereas the risk of milder complications increased at HbA~1c~ levels \>7.0% (\>53 mmol/mol). In people with HbA~1c~ levels \<6.5% (\<48 mmol/mol), clinicians should focus on avoidance of frequent hypoglycaemia and obtaining good diabetes related quality of life, or else increase the target level to 6.5-6.9% (48-52 mmol/mol). Other measures, including time in range, time in hypoglycaemia, and variation in glycaemia will be essential complementary measures to HbA~1c~ in clinical practice and future studies.

### What is already known on this topic

1.  Poor glycaemic control (high glycated haemoglobin (HbA~1c~) levels) is associated with increased risk of diabetes complications

2.  Targets for glycaemic control in children and adults differ between developed countries

3.  Low HbA~1c~ levels could increase the risk of hypoglycaemia

### What this study adds

1.  This study found no decreased risk of diabetic retinopathy and nephropathy associated with HbA~1c~ levels \<6.5% (\<48 mmol/mol) compared with 6.5-6.9% (48-52 mmol/mol) but an increased risk for severe hypoglycaemia---severe complications mainly occurred at HbA~1c~ \>8.6% and milder complications increased at \>7.0%

2.  The current findings support a general target of HbA~1c~ \<7.0% in people with type 1 diabetes

3.  People who achieve HbA~1c~ levels \<6.5% should be vigilant about not spending too much time in hypoglycaemia and achieve a good diabetes related quality of life
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